A new study finds AI can potentially detect artery calcification in routine mammograms, helping identify women at risk of ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

Suspicious cells build up in mice that haven’t given birth, a new study finds. They could help explain a longstanding mystery ...

Roche said the late-stage trial did not provide reliable evidence that ​the drug's use in combination with Pfizer's Ibrance ...

Shares fell, wiping out year-to-date gains in the company’s stock after it said the combination of giredestrant with Pfizer’s Ibrance didn’t meet its primary objective.

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...

The “Married … With Children” star was just 36 when a routine MRI in 2008 revealed early-stage breast cancer. Finding out she ...

Breast cancer remains the most common cancer affecting women in Singapore. And yet, many are still not going for regular screenings that could detect it early. To encourage more women to take the ...